Porton Newsletter | Q1 2024 Recap

Porton PharmaTech (Slovenia)-B31 R&D Labs and Kilo lab Suites (non-GMP), expected to be completed in May 2024.
New Facilities Will Be Ready in Porton USA / J-STAR
Porton's Antibody and ADC GMP Pilot Manufactory Officially Operated

Others

News 2025-07-31

Porton Participates in Publishing an OPRD Paper, Demonstrating Strength in Drug Synthesis Technology

Metal catalytic and DoE technologies for the optimization of CT1812 synthesis routes

News 2025-07-31

NMPA Approves Jike Shu (Sebaloxavir Marboxil Tablets) for the Treatment of Uncomplicated Influenza in Adults

Self-developed novel PA endonuclease inhibitor anti-influenza drug Jike Shu (Sebaloxavir Marboxil Tablets) has officially received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of uncomplicated influenza in adults.

Become part of Porton' s community to access personalized insights and resources.

First name *

Last name *

E-mail *

Company *

Subscribe for the Newsletter

Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review our Legal Disclaimer Terms and Porton Privacy.

US: (609) 860-1300
CN: (86) 23-8608-3200

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.

Submit

By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

US: (609) 860-1300
CN: (86) 23-8608-3200